Abstract
We discuss the case of a rare and often unrecognized neurologic syndrome, called Acquired Hepatocerebral Degeneration (AHD), observed in patients with advanced liver disease and portosystemic shunts. The clinical manifestations can be very heterogeneous and in our case included a combination of cerebellar and extrapyramidal signs, arisen in a period of few days. Brain Magnetic Resonance Imaging (MRI) showed, in T1-weighted images, diffuse bilateral hyper intensities in basal ganglia and biemispheric brain and cerebellar cortices, resembling paramagnetic deposits. No other neurological impairments, like stroke, infection or neoplasia, were found. It was excluded an episode of acute hepatic encephalopathy. We also ruled out Wilsonian degeneration, iron overload and autoimmune encephalitis and we lastly found high manganese levels as the possible cause of the brain paramagnetic deposits. Even though either serum Mn determination or its accumulation in the brain are not specific for AHD, however the chronic and progressively worsening of the neurological manifestations advocated a degenerative condition, possibly AHD. We finally opted for the early restoration of liver function by OLT, and we observed complete clinical symptoms’ resolution and partial MRI reversal after a follow up of 6 months.
This is a preview of subscription content, log in via an institution to check access.
References
Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, Uribe M, Vilstrup H, Morgan MY (2013) The nutritional management of hepatic encephalopathy in patients with cirrhosis: international society for hepatic encephalopathy and nitrogen metabolism consensus. Hepatology 58:325–336. https://doi.org/10.1002/hep.26370
Fernández-Rodriguez R, Contreras A, De Villoria JG, Grandas F (2010) Acquired hepatocerebral degeneration: clinical characteristics and MRI findings. Eur J Neurol 17(12):1463–1470
Fitzgeral K, Mikalunas V, Rubin H, Carthey R, Vanagunas A, Craig R (1999) Hypermanganesemia in patientsreceiving total parenteral nutrition. JPEN J Parenter Enteral Nutr 23:333–336
Huang C, Chu N, Lu C, Chen R, Schulzer M, Calne D (2007) The natural history of neurological manganism over 18 years. Parkinsonism Relat Disord 13:143–145
Klos K, Ahlskog J, Kumar N et al (2006) Brain metal concentrations in chronic liver failure patients with pallidal T1 MRI hyperintensity. Neurology 67:1984–1989
Lewis M, MacQuillan G, Bamford J, Howdle P (2000) Delayedmyelopathic presentation of the acquired hepatocerebral degeneration syndrome. Neurology 54:1011
Maffeo E, Montuschi A, Stura G, Giordana MT (2014) Chronic acquired hepatocerebral degeneration, pallidal T1 MRI hyperintensity and manganese in a series of cirrhotic patients. Neurol Sci 35(4):523–530
Miletić V, Ozretić D, Relja M (2014) Parkinsonian syndrome and ataxia as a presenting finding of acquired hepatocerebral degeneration. Metab Brain Dis 29(1):207–209
Nagura H, Yamanouchi H (1993) A case of portal-systemic shunt with progressive ataxia. Rinshoshinkeigaku 33:307–311
Qavi AH, Hammad S, Rana AI, Salih M, Shah NH, Dar FS, Ahmad A (2016) Reversal of acquired hepatocerebral degeneration with living donor liver transplantation. Liver Transpl 22(1):125–129
Quadri M, Federico A, Zhao T, Breedveld GJ, Battisti C, Delnooz C, Severijnen LA, Di Toro ML, Mignarri A, Monti L, Sanna A, Lu P, Punzo F, Cossu G, Willemsen R, Rasi F, Oostra BA, van de Warrenburg BP, Bonifati V (2012) Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet 90(3):467–477
Renjen PN, Khanna L, Rastogi R, Khan NI (2013) Acquired hepatocerebral degeneration BMJ Case Rep. 2013. https://doi.org/10.1136/bcr-2013-009387
Stracciari A, Mattarozzi K, D’Alessandro R, Baldin E, Guarino M (2008) Cognitive functioning in chronic acquired hepatocerebral degeneration. Metab Brain Dis 23:155–1609
Ueki Y, Isozaki E, Miyazaki Y, Koide R, Shimizu T, Yagi K (2002) Hirai S clinical and neuroradiological improvement in chronic acquired hepatocerebral degeneration after branched-chain amino acid therapy. Acta Neurol Scand 106(2):113–116
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P (2014) Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the liver. Hepatology 60(2):715–735. https://doi.org/10.1002/hep.27210
Yalcin D, Oguz-Akarsu E, Sokmen M (2016) Acquired hepatocerebral degeneration. Neurosciences (Riyadh) 21(2):164–167
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Pigoni, A., Iuculano, F., Saetti, C. et al. Acquired hepatocerebral degeneration (AHD): a peculiar neurological impairment in advanced chronic liver disease. Metab Brain Dis 33, 347–352 (2018). https://doi.org/10.1007/s11011-017-0107-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-017-0107-0